Chemistry:Insulin efsitora alfa
From HandWiki
| Clinical data | |
|---|---|
| Other names | LY3209590; LY-3209590 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Insulin efsitora alfa (LY3209590) is a novel insulin analog developed by Eli Lilly for the treatment of diabetes. Glycemic control and safety were found to be similar to insulin degludec in a phase II trial.[1][2][3]
References
- ↑ Heise, Tim; Chien, Jenny; Beals, John M.; Benson, Charles; Klein, Oliver; Moyers, Julie S.; Haupt, Axel; Pratt, Edward John (2023). "Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes". Diabetes, Obesity and Metabolism 25 (4): 1080–1090. doi:10.1111/dom.14956.
- ↑ Moyers, Julie S.; Hansen, Ryan J.; Day, Jonathan W.; Dickinson, Craig D.; Zhang, Chen; Ruan, Xiaoping; Ding, Liyun; Brown, Robin M. et al. (2022). "Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein". Journal of Pharmacology and Experimental Therapeutics 382 (3): 346–355. doi:10.1124/jpet.122.001105. PMID 35840338.
- ↑ Kazda, Christof M.; Bue-Valleskey, Juliana M.; Chien, Jenny; Zhang, Qianyi; Chigutsa, Emmanuel; Landschulz, William; Wullenweber, Paula; Haupt, Axel et al. (2023). "Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes". Diabetes Care 46 (5): 1052–1059. doi:10.2337/dc22-2395. PMID 36920867. PMC 10154655. https://diabetesjournals.org/care/article/46/5/1052/148588/Novel-Once-Weekly-Basal-Insulin-Fc-Achieved.
 |  |
